34603-55-9

Basic information

• Product Name: 1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde
• Synonyms: 1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde
• CAS NO: 34603-55-9
• Molecular Weight: 176.215
• Mol File: 34603-55-9.mol

Chemical Properties

• CAS DataBase Reference: 1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde(34603-55-9)
• EPA Substance Registry System: 1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde(34603-55-9)

Safety Data

• Hazardous Substances Data: 34603-55-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde is used as a key building block in the synthesis of various organic compounds. Its unique structure and reactivity make it a versatile component for constructing complex molecules, which can be applied across different industries.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde is used as a precursor for the development of novel pharmaceuticals. Its potential biological and pharmacological activities, such as its antineoplastic properties, make it a promising candidate for further research and drug discovery.
Used in the Pharmaceutical Industry:
1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde is employed as an intermediate in the production of pharmaceuticals, particularly those with antineoplastic properties. Its ability to be modified and incorporated into various drug molecules contributes to its significance in this industry.
Used in the Chemical Research Industry:
1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde is also used as a research tool in the chemical research industry. Its unique properties and reactivity make it an ideal candidate for studying various chemical reactions and mechanisms, furthering our understanding of organic chemistry and potentially leading to the discovery of new compounds and applications.

Upstream product

• 16728-00-0 1-(4-methoxyphenyl)cyclopropane-1-carbonitrile 
• 164171-78-2 1-cyclobutenyl-4-methoxybenzene 
• 215038-69-0 1-(4-methoxyphenyl)cyclobutyl acetate 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 16728-01-1 1-(4-methoxyphenyl)-1-cyclopropanecarboxylic acid 
• 16728-03-3 1-(4-Methoxyphenyl)cyclopropyl-1-carbinol 

Downstream Products

• 1029714-80-4 1-methoxy-4-[1-[(E)-2-methoxyvinyl]cyclopropyl]benzene 
• 1258388-76-9 (Z)-1-(1-(buta-1,3-dienyl)cyclopropyl)-4-methoxybenzene 

Relevant articles and documents

Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl- l -methionine Pocket

A fragment screening approach designed to target specifically the S-adenosyl-l-methionine pocket of catechol O-methyl transferase allowed the identification of structurally related fragments of high ligand efficiency and with activity on the described orthogonal assays. By use of a reliable enzymatic assay together with X-ray crystallography as guidance, a series of fragment modifications revealed an SAR and, after several expansions, potent lead compounds could be obtained. For the first time nonphenolic and small low nanomolar potent, SAM competitive COMT inhibitors are reported. These compounds represent a novel series of potent COMT inhibitors that might be further optimized to new drugs useful for the treatment of Parkinson's disease, as adjuncts in levodopa based therapy, or for the treatment of schizophrenia.

Synthesizing Molecules with Linear Tricyclic 5/5/5 and 6/5/5 Skeletons via [5 + 2 + 1]/Ene Strategy

Report here is the development of a [5 + 2 + 1]/ene strategy for the synthesis of molecules with linear tricyclic 5/5/5 and 6/5/5 skeletons widely found in natural products. The first step of this strategy is applying a Rh-catalyzed [5 + 2 + 1] reaction o

COMPOUNDS FOR TREATING AND PREVENTING GROWTH HORMONE RECEPTOR-DEPENDENT CONDITIONS

The invention relates to compounds, in particular pyrimidine-2,4-diamines, analogues and salts thereof and pharmaceutical compositions comprising pyrimidine-2,4-diamines analogues and salts thereof for use in the treatment and prevention of a disease, in particular a growth hormone receptor-dependent condition. The invention also relates to methods of using these compounds and compositions to treat physiological dsorders related to the amount or activity of growth hormone. In a particular embodiment, the invention relates to a compound according to formula 1 for use in the treatment or prevention of a disease in a subject

Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809

The 1,2,3-triazole has been successfully utilized as an amide bioisostere in multiple therapeutic contexts. Based on this precedent, triazole analogues derived from VX-809 and VX-770, prominent amide-containing modulators of the cystic fibrosis transmembrane conductance regulator (CFTR), were synthesized and evaluated for CFTR modulation. Triazole 11, derived from VX-809, displayed markedly reduced efficacy in F508del-CFTR correction in cellular TECC assays in comparison to VX-809. Surprisingly, triazole analogues derived from potentiator VX-770 displayed no potentiation of F508del, G551D, or WT-CFTR in cellular Ussing chamber assays. However, patch clamp analysis revealed that triazole 60 potentiates WT-CFTR similarly to VX-770. The efficacy of 60 in the cell-free patch clamp experiment suggests that the loss of activity in the cellular assay could be due to the inability of VX-770 triazole derivatives to reach the CFTR binding site. Moreover, in addition to the negative impact on biological activity, triazoles in both structural classes displayed decreased metabolic stability in human microsomes relative to the analogous amides. In contrast to the many studies that demonstrate the advantages of using the 1,2,3-triazole, these findings highlight the negative impacts that can arise from replacement of the amide with the triazole and suggest that caution is warranted when considering use of the 1,2,3-triazole as an amide bioisostere.

Oxidative Ring Contraction of Cyclobutenes: General Approach to Cyclopropylketones including Mechanistic Insights

An original oxidative ring contraction of easily accessible cyclobutene derivatives for the selective formation of cyclopropylketones (CPKs) under atmospheric conditions is reported. Comprehensive mechanistic studies are proposed to support this novel, yet unusual, rearrangement. Insights into the mechanism ultimately led to simplification and generalization of the ring contraction of cyclobutenes using mCPBA as an oxidant. This unique and functional group tolerant transformation proceeds under mild conditions at room temperature, providing access to a new library of polyfunctionalized motifs. With CPKs being attractive and privileged pharmacophores, the elaboration of such a simple and straightforward strategy represents a highly valuable tool for drug discovery and medicinal chemistry. Additionally, the described method was employed to generate a pool of bioactive substances and key precursors in a minimum number of steps.

BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS

The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME

It is to provide a novel compound useful for preventing and/or treating diseases that involves 11β-hydroxysteroid dehydrogenase 1, particularly diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metab